{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:56:19Z","timestamp":1792090579109,"version":"4.4.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The historical use of the term non-alcoholic fatty liver disease (NAFLD) in obese\/overweight children has been controversial as to the appropriateness of this terminology in children, and lately, in adults too. Newer game-changer terminology, metabolic (dysfunction)-associated fatty liver disease (MAFLD), for this condition signifies a positive step forward that addresses the limitations of the previous definition for both adults and children. The prevalence of MAFLD has surged in tandem with the global rise in obesity rates, establishing itself as a predominant cause of chronic liver disease in both adult and pediatric populations. The adoption of the recently proposed nomenclature reflects a more encompassing comprehension of the disease and its etiology compared to its predecessor, NAFLD. Notably, the revised terminology facilitates the recognition of MAFLD as an autonomous condition while acknowledging the potential coexistence of other systemic fatty liver disorders. Particularly in children, this includes various paediatric-onset genetic and inherited metabolic disorders, necessitating thorough exclusion, especially in cases where weight loss interventions yield no improvement or in the absence of obesity. MAFLD presents as a multifaceted disorder; evidence suggests its origins lie in a complex interplay of nutritional, genetic, hormonal, and environmental factors. Despite advancements, current non-invasive diagnostic biomarkers exhibit limitations in accuracy, often necessitating imaging and histological evaluations for definitive diagnosis. While dietary and lifestyle modifications stand as cornerstone measures for MAFLD prevention and management, ongoing evaluation of therapeutic agents continues. This article provides an overview of the latest developments and emerging therapies in the realm of paediatric MAFLD.<\/jats:p>","DOI":"10.1007\/s12072-024-10691-5","type":"journal-article","created":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T03:01:31Z","timestamp":1718506891000},"page":"873-883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5289-6537","authenticated-orcid":false,"given":"Sunitha","family":"Vimalesvaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Vajro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,16]]},"reference":[{"issue":"16","key":"10691_CR1","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.3390\/ijms21165888","volume":"21","author":"A Lonardo","year":"2020","unstructured":"Lonardo A, Leoni S, Alswat KA, Fouad Y. History of nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21(16):5888","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10691_CR2","first-page":"169","volume":"5","author":"R Alfani","year":"2018","unstructured":"Alfani R, Vassallo E, De Anseris AG, Nazzaro L, D\u2019Acunzo I, Porfito C, et al. Pediatric fatty liver and obesity: not always justa matter of non-alcoholic fatty liver disease. Children (Basel). 2018;5(12):169","journal-title":"Children (Basel)"},{"issue":"6","key":"10691_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jhep.2018.02.006","volume":"68","author":"R Hegarty","year":"2018","unstructured":"Hegarty R, Deheragoda M, Fitzpatrick E, Dhawan A. Paediatric fatty liver disease (PeFLD): all is not NAFLD - Pathophysiological insights and approach to management. J Hepatol. 2018;68(6):1286\u20131299","journal-title":"J Hepatol"},{"issue":"10","key":"10691_CR4","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864\u2013873","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5\u20136","key":"10691_CR5","first-page":"481","volume":"28","author":"W Kiess","year":"2015","unstructured":"Kiess W, Penke M, Sergeyev E, Neef M, Adler M, Gausche R, et al. Childhood obesity at the crossroads. J Pediatr Endocrinol Metab. 2015;28(5\u20136):481\u2013484","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"10691_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jpeds.2012.08.043","volume":"162","author":"JA Welsh","year":"2013","unstructured":"Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988\u20131994 to 2007\u20132010. J Pediatr. 2013;162(3):496-500 e1","journal-title":"J Pediatr"},{"issue":"3","key":"10691_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2468-1253(19)30419-4","volume":"5","author":"KWM Abeysekera","year":"2020","unstructured":"Abeysekera KWM, Fernandes GS, Hammerton G, Portal AJ, Gordon FH, Heron J, et al. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. Lancet Gastroenterol Hepatol. 2020;5(3):295\u2013305","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10691_CR8","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1111\/liv.15080","volume":"42","author":"ZY Zou","year":"2022","unstructured":"Zou ZY, Zeng J, Ren TY, Huang LJ, Wang MY, Shi YW, et al. The burden and sexual dimorphism with nonalcoholic fatty liver disease in Asian children: a systematic review and meta-analysis. Liver Int. 2022;42(9):1969\u20131980","journal-title":"Liver Int"},{"issue":"1","key":"10691_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0038-1627456","volume":"38","author":"JP Mann","year":"2018","unstructured":"Mann JP, Valenti L, Scorletti E, Byrne CD, Nobili V. Nonalcoholic fatty liver disease in children. Semin Liver Dis. 2018;38(1):1\u201313","journal-title":"Semin Liver Dis"},{"issue":"9","key":"10691_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41575-019-0169-z","volume":"16","author":"V Nobili","year":"2019","unstructured":"Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol. 2019;16(9):517\u2013530","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10691_CR11","doi-asserted-by":"publisher","first-page":"e4046","DOI":"10.1210\/clinem\/dgaa583","volume":"105","author":"A Morandi","year":"2020","unstructured":"Morandi A, Di Sessa A, Zusi C, Umano GR, El Mazloum D, Fornari E, et al. Nonalcoholic fatty liver disease and estimated insulin resistance in obese youth: a mendelian randomization analysis. J Clin Endocrinol Metab. 2020;105(11):e4046\u2013e4054","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10691_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"4","key":"10691_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jhep.2020.12.025","volume":"74","author":"M Eslam","year":"2021","unstructured":"Eslam M, Ratziu V, George J. Yet more evidence that MAFLD is more than a name change. J Hepatol. 2021;74(4):977\u2013979","journal-title":"J Hepatol"},{"issue":"7","key":"10691_CR14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014 e1","journal-title":"Gastroenterology"},{"issue":"5","key":"10691_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/MPG.0000000000003919","volume":"77","author":"K Rupasinghe","year":"2023","unstructured":"Rupasinghe K, Hind J, Hegarty R. Updates in metabolic dysfunction-associated fatty liver disease (MAFLD) in children. J Pediatr Gastroenterol Nutr. 2023;77(5):583\u2013591","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"11","key":"10691_CR16","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.3390\/nu12113531","volume":"12","author":"G Alberti","year":"2020","unstructured":"Alberti G, Gana JC, Santos JL. Fructose, omega 3 fatty acids, and Vitamin E: involvement in pediatric non-alcoholic fatty liver disease. Nutrients. 2020;12(11):3531","journal-title":"Nutrients"},{"issue":"10","key":"10691_CR17","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.3390\/nu12103166","volume":"12","author":"A Mandala","year":"2020","unstructured":"Mandala A, Janssen RC, Palle S, Short KR, Friedman JE. Pediatric non-alcoholic fatty liver disease: nutritional origins and potential molecular mechanisms. Nutrients. 2020;12(10):3166","journal-title":"Nutrients"},{"issue":"8","key":"10691_CR18","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.3390\/nu6083187","volume":"6","author":"R Jin","year":"2014","unstructured":"Jin R, Welsh JA, Le NA, Holzberg J, Sharma P, Martin DR, et al. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients. 2014;6(8):3187\u20133201","journal-title":"Nutrients"},{"issue":"7","key":"10691_CR19","doi-asserted-by":"publisher","first-page":"e12630","DOI":"10.1111\/ijpo.12630","volume":"15","author":"AM Goss","year":"2020","unstructured":"Goss AM, Dowla S, Pendergrass M, Ashraf A, Bolding M, Morrison S, et al. Effects of a carbohydrate-restricted diet on hepatic lipid content in adolescents with non-alcoholic fatty liver disease: a pilot, randomized trial. Pediatr Obes. 2020;15(7):e12630","journal-title":"Pediatr Obes"},{"issue":"12","key":"10691_CR20","doi-asserted-by":"publisher","first-page":"9721","DOI":"10.3390\/nu7125494","volume":"7","author":"PS Gibson","year":"2015","unstructured":"Gibson PS, Lang S, Gilbert M, Kamat D, Bansal S, Ford-Adams ME, et al. Assessment of diet and physical activity in paediatric non-alcoholic fatty liver disease patients: a United Kingdom case control study. Nutrients. 2015;7(12):9721\u20139733","journal-title":"Nutrients"},{"issue":"5","key":"10691_CR21","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/MPG.0000000000000267","volume":"58","author":"TA O'Sullivan","year":"2014","unstructured":"O\u2019Sullivan TA, Oddy WH, Bremner AP, Sherriff JL, Ayonrinde OT, Olynyk JK, et al. Lower fructose intake may help protect against development of nonalcoholic fatty liver in adolescents with obesity. J Pediatr Gastroenterol Nutr. 2014;58(5):624\u2013631","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10691_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jama.2018.20579","volume":"321","author":"JB Schwimmer","year":"2019","unstructured":"Schwimmer JB, Ugalde-Nicalo P, Welsh JA, Angeles JE, Cordero M, Harlow KE, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial. JAMA. 2019;321(3):256\u2013265","journal-title":"JAMA"},{"issue":"4","key":"10691_CR23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","volume":"114","author":"CP Day","year":"1998","unstructured":"Day CP, James OF. Steatohepatitis: a tale of two \u201chits\u201d? Gastroenterology. 1998;114(4):842\u2013845","journal-title":"Gastroenterology"},{"issue":"2","key":"10691_CR24","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.31518","volume":"73","author":"H Tilg","year":"2021","unstructured":"Tilg H, Adolph TE, Moschen AR. Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade. Hepatology. 2021;73(2):833\u2013842","journal-title":"Hepatology"},{"issue":"5","key":"10691_CR25","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836\u20131846","journal-title":"Hepatology"},{"issue":"3","key":"10691_CR26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1073\/pnas.0605374104","volume":"104","author":"F Backhed","year":"2007","unstructured":"Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104(3):979\u2013984","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7122","key":"10691_CR27","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nature05414","volume":"444","author":"PJ Turnbaugh","year":"2006","unstructured":"Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027\u20131031","journal-title":"Nature"},{"issue":"2","key":"10691_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jcmgh.2019.09.009","volume":"9","author":"HQ Tran","year":"2020","unstructured":"Tran HQ, Bretin A, Adeshirlarijaney A, Yeoh BS, Vijay-Kumar M, Zou J, et al. \u201cWestern Diet\u201d-induced adipose inflammation requires a complex gut microbiota. Cell Mol Gastroenterol Hepatol. 2020;9(2):313\u2013333","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"10691_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.21037\/hbsn.2020.03.27","volume":"10","author":"C Mandato","year":"2021","unstructured":"Mandato C, Delli Bovi AP, Vajro P. The gut-liver axis as a target of liver disease management. Hepatobiliary Surg Nutr. 2021;10(1):100\u2013102","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"6","key":"10691_CR30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/ijpo.12164","volume":"12","author":"S Guercio Nuzio","year":"2017","unstructured":"Guercio Nuzio S, Di Stasi M, Pierri L, Troisi J, Poeta M, Bisogno A, et al. Multiple gut-liver axis abnormalities in children with obesity with and without hepatic involvement. Pediatr Obes. 2017;12(6):446\u2013452","journal-title":"Pediatr Obes"},{"issue":"2","key":"10691_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1055\/s-0042-1748037","volume":"42","author":"B Gupta","year":"2022","unstructured":"Gupta B, Rai R, Oertel M, Raeman R. Intestinal barrier dysfunction in fatty liver disease: roles of microbiota, mucosal immune system, and bile acids. Semin Liver Dis. 2022;42(2):122\u2013137","journal-title":"Semin Liver Dis"},{"key":"10691_CR32","doi-asserted-by":"publisher","first-page":"700058","DOI":"10.3389\/fnut.2021.700058","volume":"8","author":"D Tokuhara","year":"2021","unstructured":"Tokuhara D. Role of the gut microbiota in regulating non-alcoholic fatty liver disease in children and adolescents. Front Nutr. 2021;8:700058","journal-title":"Front Nutr"},{"issue":"4","key":"10691_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.clinre.2018.03.015","volume":"42","author":"L Pierri","year":"2018","unstructured":"Pierri L, Saggese P, Guercio Nuzio S, Troisi J, Di Stasi M, Poeta M, et al. Relations of gut liver axis components and gut microbiota in obese children with fatty liver: a pilot study. Clin Res Hepatol Gastroenterol. 2018;42(4):387\u2013390","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"10691_CR34","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1053\/j.gastro.2019.06.028","volume":"157","author":"JB Schwimmer","year":"2019","unstructured":"Schwimmer JB, Johnson JS, Angeles JE, Behling C, Belt PH, Borecki I, et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology. 2019;157(4):1109\u20131122","journal-title":"Gastroenterology"},{"issue":"2","key":"10691_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/pr.2018.32","volume":"84","author":"MA Stanislawski","year":"2018","unstructured":"Stanislawski MA, Lozupone CA, Wagner BD, Eggesbo M, Sontag MK, Nusbacher NM, et al. Gut microbiota in adolescents and the association with fatty liver: the EPOCH study. Pediatr Res. 2018;84(2):219\u2013227","journal-title":"Pediatr Res"},{"issue":"2","key":"10691_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/hep.28572","volume":"65","author":"F Del Chierico","year":"2017","unstructured":"Del Chierico F, Nobili V, Vernocchi P, Russo A, De Stefanis C, Gnani D, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65(2):451\u2013464","journal-title":"Hepatology"},{"issue":"2","key":"10691_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/femsec\/fiu002","volume":"91","author":"S Michail","year":"2015","unstructured":"Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015;91(2):1\u20139","journal-title":"FEMS Microbiol Ecol"},{"issue":"2","key":"10691_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","volume":"57","author":"L Zhu","year":"2013","unstructured":"Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601\u2013609","journal-title":"Hepatology"},{"key":"10691_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.coemr.2021.05.003","volume":"19","author":"NH Salzman","year":"2021","unstructured":"Salzman NH, Schwimmer JB. Pediatric nonalcoholic fatty liver disease and the microbiome: Mechanisms contributing to pathogenesis and progression. Curr Opin Endocr Metab Res. 2021;19:22\u201329","journal-title":"Curr Opin Endocr Metab Res"},{"issue":"1","key":"10691_CR40","doi-asserted-by":"publisher","first-page":"102921","DOI":"10.1016\/j.dsx.2023.102921","volume":"18","author":"S Zhao","year":"2023","unstructured":"Zhao S, Zhang L, Zhao J, Kota VG, Venkat KM, Tasnim F, et al. Characteristics of contemporary drug clinical trials regarding the treatment of non-alcoholic steatohepatitis. Diabetes Metab Syndr. 2023;18(1):102921","journal-title":"Diabetes Metab Syndr"},{"issue":"3","key":"10691_CR41","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jhep.2021.12.024","volume":"76","author":"EK Speliotes","year":"2022","unstructured":"Speliotes EK, George J. Metabolic and genetic contributions to NAFLD: really distinct and homogeneous? J Hepatol. 2022;76(3):498\u2013500","journal-title":"J Hepatol"},{"key":"10691_CR42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jpeds.2017.08.004","volume":"190","author":"J Wattacheril","year":"2017","unstructured":"Wattacheril J, Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, et al. Genome-Wide Associations Related to Hepatic Histology in Nonalcoholic Fatty Liver Disease in Hispanic Boys. J Pediatr. 2017;190:100-107 e2","journal-title":"J Pediatr"},{"issue":"2","key":"10691_CR43","doi-asserted-by":"publisher","first-page":"e12852","DOI":"10.1111\/ijpo.12852","volume":"17","author":"KJ Lee","year":"2022","unstructured":"Lee KJ, Moon JS, Kim NY, Ko JS. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children. Pediatr Obes. 2022;17(2):e12852","journal-title":"Pediatr Obes"},{"key":"10691_CR44","doi-asserted-by":"publisher","first-page":"204201882311603","DOI":"10.1177\/20420188231160388","volume":"14","author":"R Hegarty","year":"2023","unstructured":"Hegarty R, Kyrana E, Fitzpatrick E, Dhawan A. Fatty liver disease in children (MAFLD\/PeFLD Type 2): unique classification considerations and challenges. Ther Adv Endocrinol Metab. 2023;14:20420188231160388","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10691_CR45","doi-asserted-by":"publisher","first-page":"1006008","DOI":"10.3389\/fendo.2022.1006008","volume":"13","author":"N Panera","year":"2022","unstructured":"Panera N, Mandato C, Crudele A, Bertrando S, Vajro P, Alisi A. Genetics, epigenetics and transgenerational transmission of obesity in children. Front Endocrinol (Lausanne). 2022;13:1006008","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10691_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-981-10-5526-3_4","volume":"1012","author":"H Itoh","year":"2018","unstructured":"Itoh H, Kanayama N. Developmental origins of nonalcoholic fatty liver disease (NAFLD). Adv Exp Med Biol. 2018;1012:29\u201339","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10691_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrgastro.2016.160","volume":"14","author":"SR Wesolowski","year":"2017","unstructured":"Wesolowski SR, Kasmi KC, Jonscher KR, Friedman JE. Developmental origins of NAFLD: a womb with a clue. Nat Rev Gastroenterol Hepatol. 2017;14(2):81\u201396","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10691_CR48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jhep.2017.04.016","volume":"67","author":"A Alisi","year":"2017","unstructured":"Alisi A, Vajro P. Pre-natal and post-natal environment monitoring to prevent non-alcoholic fatty liver disease development. J Hepatol. 2017;67(3):451\u2013453","journal-title":"J Hepatol"},{"issue":"2","key":"10691_CR49","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/MPG.0000000000000520","volume":"60","author":"KR Patel","year":"2015","unstructured":"Patel KR, White FV, Deutsch GH. Hepatic steatosis is prevalent in stillborns delivered to women with diabetes mellitus. J Pediatr Gastroenterol Nutr. 2015;60(2):152\u2013158","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10691_CR50","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/gut.2003.019984","volume":"53","author":"S Dam-Larsen","year":"2004","unstructured":"Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53(5):750\u2013755","journal-title":"Gut"},{"issue":"10","key":"10691_CR51","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.3390\/diagnostics12102287","volume":"12","author":"D Bozic","year":"2022","unstructured":"Bozic D, Podrug K, Mikolasevic I, Grgurevic I. Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal. Diagnostics (Basel). 2022;12(10):2287","journal-title":"Diagnostics (Basel)"},{"key":"10691_CR52","doi-asserted-by":"publisher","first-page":"160-4 e1","DOI":"10.1016\/j.jpeds.2016.03.021","volume":"173","author":"NK Desai","year":"2016","unstructured":"Desai NK, Harney S, Raza R, Al-Ibraheemi A, Shillingford N, Mitchell PD, et al. Comparison of Controlled Attenuation Parameter and Liver Biopsy to Assess Hepatic Steatosis in Pediatric Patients. J Pediatr. 2016;173:160\u20134 e1","journal-title":"J Pediatr"},{"issue":"3","key":"10691_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","volume":"6","author":"D Petroff","year":"2021","unstructured":"Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(3):185\u2013198","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10691_CR54","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1002\/hep.28699","volume":"64","author":"WN Hannah Jr","year":"2016","unstructured":"Hannah WN Jr, Harrison SA. Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2016;64(6):2234\u20132243","journal-title":"Hepatology"},{"issue":"3","key":"10691_CR55","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/hep.29596","volume":"67","author":"MS Middleton","year":"2018","unstructured":"Middleton MS, Van Natta ML, Heba ER, Alazraki A, Trout AT, Masand P, et al. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology. 2018;67(3):858\u2013872","journal-title":"Hepatology"},{"issue":"8","key":"10691_CR56","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1053\/j.gastro.2016.03.009","volume":"150","author":"V Nobili","year":"2016","unstructured":"Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease. Gastroenterology. 2016;150(8):1798\u20131810","journal-title":"Gastroenterology"},{"issue":"2","key":"10691_CR57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cld.2015.10.011","volume":"20","author":"DE Kleiner","year":"2016","unstructured":"Kleiner DE, Makhlouf HR. Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clin Liver Dis. 2016;20(2):293\u2013312","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10691_CR58","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","volume":"64","author":"MB Vos","year":"2017","unstructured":"Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319\u2013334","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10691_CR59","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cld.2015.10.003","volume":"20","author":"NP Goyal","year":"2016","unstructured":"Goyal NP, Schwimmer JB. The progression and natural history of pediatric nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20(2):325\u2013338","journal-title":"Clin Liver Dis"},{"issue":"5","key":"10691_CR60","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/MPG.0b013e318252a13f","volume":"54","author":"P Vajro","year":"2012","unstructured":"Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012;54(5):700\u2013713","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10691_CR61","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4254\/wjh.v15.i5.609","volume":"15","author":"D Jayasekera","year":"2023","unstructured":"Jayasekera D, Hartmann P. Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease. World J Hepatol. 2023;15(5):609\u2013640","journal-title":"World J Hepatol"},{"issue":"2","key":"10691_CR62","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.cgh.2010.09.015","volume":"9","author":"N Alkhouri","year":"2011","unstructured":"Alkhouri N, Carter-Kent C, Lopez R, Rosenberg WM, Pinzani M, Bedogni G, et al. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol. 2011;9(2):150\u2013155","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10691_CR63","doi-asserted-by":"publisher","first-page":"e104558","DOI":"10.1371\/journal.pone.0104558","volume":"9","author":"N Alkhouri","year":"2014","unstructured":"Alkhouri N, Mansoor S, Giammaria P, Liccardo D, Lopez R, Nobili V. The development of the pediatric NAFLD fibrosis score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease. PLoS\u00a0One. 2014;9(8):e104558","journal-title":"PLoS\u00a0One"},{"issue":"10","key":"10691_CR64","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/medicina59101785","volume":"59","author":"N Garibay-Nieto","year":"2023","unstructured":"Garibay-Nieto N, Pedraza-Escudero K, Omana-Guzman I, Garces-Hernandez MJ, Villanueva-Ortega E, Flores-Torres M, et al. Metabolomic phenotype of hepatic steatosis and fibrosis in mexican children living with obesity. Medicina (Kaunas). 2023;59(10):1785","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10691_CR65","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/nu11020274","volume":"11","author":"J Troisi","year":"2019","unstructured":"Troisi J, Belmonte F, Bisogno A, Pierri L, Colucci A, Scala G, et al. Metabolomic Salivary Signature of Pediatric Obesity Related Liver Disease and Metabolic Syndrome. Nutrients. 2019;11(2):274","journal-title":"Nutrients"},{"issue":"5","key":"10691_CR66","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/nu9050485","volume":"9","author":"J Troisi","year":"2017","unstructured":"Troisi J, Pierri L, Landolfi A, Marciano F, Bisogno A, Belmonte F, et al. Urinary metabolomics in pediatric obesity and NAFLD identifies metabolic pathways\/metabolites related to dietary habits and gut-liver axis perturbations. Nutrients. 2017;9(5):485","journal-title":"Nutrients"},{"issue":"22","key":"10691_CR67","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.3390\/nu15224829","volume":"15","author":"C Farias","year":"2023","unstructured":"Farias C, Cisternas C, Gana JC, Alberti G, Echeverria F, Videla LA, et al. Dietary and nutritional interventions in nonalcoholic fatty liver disease in pediatrics. Nutrients. 2023;15(22):4829","journal-title":"Nutrients"},{"issue":"4","key":"10691_CR68","first-page":"12","volume":"Suppl 4","author":"DF Chan","year":"2018","unstructured":"Chan DF, Nelson EA, Li AM, Woo J, Sea MM, Chan RS, et al. Lifestyle intervention in obese Chinese adolescents with non-alcoholic fatty liver disease: a randomised controlled study. Hong Kong Med J Suppl. 2018;Suppl 4(4):12\u201315","journal-title":"Hong Kong Med J Suppl"},{"key":"10691_CR69","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4274\/jpr.galenos.2020.26042","volume":"8","author":"P Malecki","year":"2021","unstructured":"Malecki P, Mania A, Mazur-Melewska K, Sluzewski W, Figlerowicz M. A decline in aminotransferase activity due to lifestyle modification in children with NAFLD. J Pediatr Res. 2021;8:41\u201348","journal-title":"J Pediatr Res"},{"issue":"2","key":"10691_CR70","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MPG.0b013e31822cdedf","volume":"54","author":"H Gronbaek","year":"2012","unstructured":"Gronbaek H, Lange A, Birkebaek NH, Holland-Fischer P, Solvig J, Horlyck A, et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr. 2012;54(2):223\u2013228","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"16","key":"10691_CR71","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.2011.520","volume":"305","author":"JE Lavine","year":"2011","unstructured":"Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of Vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659\u20131668","journal-title":"JAMA"},{"issue":"3","key":"10691_CR72","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1097\/MPG.0000000000003537","volume":"75","author":"N Gkiourtzis","year":"2022","unstructured":"Gkiourtzis N, Kalopitas G, Vadarlis A, Bakaloudi DR, Dionysopoulos G, Karanika E, et al. The benefit of probiotics in pediatric nonalcoholic fatty liver disease: a meta-analysis of randomized control trials. J Pediatr Gastroenterol Nutr. 2022;75(3):e31\u2013e37","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"10","key":"10691_CR73","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1111\/jgh.16256","volume":"38","author":"L Rong","year":"2023","unstructured":"Rong L, Ch\u2019ng D, Jia P, Tsoi KKF, Wong SH, Sung JJY. Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2023;38(10):1682\u20131694","journal-title":"J Gastroenterol Hepatol"},{"issue":"27","key":"10691_CR74","doi-asserted-by":"publisher","first-page":"8545","DOI":"10.1080\/10408398.2022.2062589","volume":"63","author":"G Dionysopoulos","year":"2023","unstructured":"Dionysopoulos G, Kalopitas G, Vadarlis A, Bakaloudi DR, Gkiourtzis N, Karanika E, et al. Can omega-3 fatty acids be beneficial in pediatric NAFLD? a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2023;63(27):8545\u20138553","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"6","key":"10691_CR75","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/17474124.2022.2083605","volume":"16","author":"X Lin","year":"2022","unstructured":"Lin X, Mai M, He T, Huang H, Zhang P, Xia E, et al. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2022;16(6):537\u2013545","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"6","key":"10691_CR76","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0022-3476(00)26774-7","volume":"136","author":"P Vajro","year":"2000","unstructured":"Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr. 2000;136(6):739\u2013743","journal-title":"J Pediatr"},{"issue":"Suppl 1","key":"10691_CR77","first-page":"S46","volume":"12","author":"PP Roy","year":"2022","unstructured":"Roy PP, Mahtab MA, Rahim MA, Yesmin SS, Islam SB, Akbar SMF. Treatment of nonalcoholic steatohepatitis by obeticholic acid: current status. Euroasian J Hepatogastroenterol. 2022;12(Suppl 1):S46\u2013S50","journal-title":"Euroasian J Hepatogastroenterol"},{"issue":"4","key":"10691_CR78","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/MPG.0000000000000715","volume":"60","author":"V Nobili","year":"2015","unstructured":"Nobili V, Vajro P, Dezsofi A, Fischler B, Hadzic N, Jahnel J, et al. Indications and limitations of bariatric intervention in severely obese children and adolescents with and without nonalcoholic steatohepatitis: ESPGHAN hepatology committee position statement. J Pediatr Gastroenterol Nutr. 2015;60(4):550\u2013561","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10691_CR79","first-page":"372","volume":"8","author":"H Till","year":"2021","unstructured":"Till H, Mann O, Singer G, Weihrauch-Bluher S. Update on metabolic bariatric surgery for morbidly obese adolescents. Children (Basel). 2021;8(5):372","journal-title":"Children (Basel)"},{"key":"10691_CR80","doi-asserted-by":"publisher","first-page":"1182037","DOI":"10.3389\/fendo.2023.1182037","volume":"14","author":"T Kongmalai","year":"2023","unstructured":"Kongmalai T, Srinonprasert V, Anothaisintawee T, Kongmalai P, McKay G, Attia J, et al. New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023;14:1182037","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"10691_CR81","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/hep4.1601","volume":"4","author":"JJ Witjes","year":"2020","unstructured":"Witjes JJ, Smits LP, Pekmez CT, Prodan A, Meijnikman AS, Troelstra MA, et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis. Hepatol Commun. 2020;4(11):1578\u20131590","journal-title":"Hepatol Commun"},{"issue":"9","key":"10691_CR82","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s12519-022-00655-w","volume":"19","author":"X Gu","year":"2023","unstructured":"Gu X, Chen ZH, Zhang SC. Fecal microbiota transplantation in childhood: past, present, and future. World J Pediatr. 2023;19(9):813\u2013822","journal-title":"World J Pediatr"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10691-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10691-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10691-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T14:06:30Z","timestamp":1727964390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10691-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,16]]},"references-count":82,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10691"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10691-5","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,16]]},"assertion":[{"value":"10 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SV, PV and AD declare that they have no conflict of interest. AD sits on the scientific advisory boards for MSD, Alexion, Univar, BitBio, Aspect Bio and Treefrog Bio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not required for this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not applicable for this review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}